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Abstract  
Objectives: The purpose of this study was to compare radiographic outcomes according to 
the magnitude of the response utilizing three new psoriatic composite disease activity 
measures (the Psoriatic Arthritis Disease Activity Score (PASDAS), the GRAPPA Composite 
Exercise (GRACE), and the Disease Activity in PsA (DAPSA). The data were taken from the 
GO-REVEAL dataset, a large randomised, double-blind, study which evaluated the safety 
and efficacy of 2 doses of the TNF inhibitor golimumab in subjects with active PsA.  
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Methods: Response criteria at 24 weeks were applied across the whole dataset, 
irrespective of treatment group. Radiographic scores at baseline and 24 weeks were 
assessed using the Sharp van der Heijde method, modified for PsA.   
Results: Overall, for each measure, radiographic progression was significantly greater in 
subjects with a moderate or poor outcome, and absent in those with a good outcome. The 
proportion of subjects without radiographic progression in the good outcome group was: 
PASDAS, 83% , Ȥ 7.9, p = 0.02 ; GRACE, Ȥ 5.8, p = 0.05 ; DAPSAȤ 
3.4, p = 0.19. 
Conclusions: Response criteria for disease specific composite measures enable separation 
between groups in terms of radiographic progression and may therefore be used as suitable 
targets for interventional studies, as well as in the clinic. 
 
Key words: psoriasis, psoriatic arthritis, outcome measures, TNF inhibitors, golimumab, 
radiographic scoring  
 
Significance and innovation 
x Some new composite disease activity measures for psoriatic arthritis measure across 
the disease spectrum, others are mainly articular based.  
x Irrespective of the spectrum of disease manifestations assessed, each of the 
measures were able to distinguish between a good, moderate and poor outcome, 
based on radiographic progression. 
x New composite disease activity measures, and their response criteria, are suitable 
targets for interventional studies, and in the clinic. 
 
Introduction 
PsA is a heterogeneous disease, characterized by involvement of skin and nails, peripheral 
joints, entheses, and axial joints. To comprehensively assess disease activity in 
heterogeneous conditions, such as PsA, and also to assess changes in disease activity with 
time, composite measures should assess all relevant clinical outcomes. Composite  
measures may incorporate several dimensions of disease status by combining  different 
domains into a single score.  Composite measures can potentially provide a summary 
outcome for different groups of signs and symptoms at a specific time point.  
In rheumatoid arthritis controlling disease activity inhibits the  progression of peripheral joint 
damage as assessed radiographically;  a similar paradigm  appears to occur in PsA (1). The 
GO-REVEAL trial demonstrated improvement across clinical domains as well as inhibition of 
radiographic progression  with the use of a highly efficacious medication, the TNF inhibitor 
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golimumab (2),  Data from the study offered the opportunity to examine radiographic 
progression according to clinical outcomes based on newly developed, PsA specific, 
composite measures. 
Methods 
These analyses used data from the GO-REVEAL study (2). Briefly, the GO-REVEAL study 
was a randomised placebo controlled trial of golimumab in 405 patients with active, 
predominantly polyarticular, PsA. The definition of active psoriatic arthritis included the 
presence of at least 3 swollen and 3 tender joints and and the presence of plaque psoriasis 
with a qualifying lesion at least 2 cm in diameter. Patients were required to have active 
disease despite treatment with disease modifying drugs but prior treatment with biologic 
drugs was prohibited. Patients were randomized to receive treatment with  placebo, or with 
golimumab at doses of 50mg or 100 mg subcutaneously every 4 weeks. Patients not 
achieving a 10% reduction in swollen and tender joint count at week 16 (n = 87) were re-
randomised (placebo to golimumab 50mg, golimumab 50mg to golimumab 100mg and 
golimumab 100mg remained on the same treatment) until the end of the placebo controlled 
phase at week 24.  Data from a random sample of all GO-REVEAL patients (n=312) at 
baseline and 24 weeks were avaialbe for this analysis, but analysis was confined to those 
patients at week 24 who were in their original allocated treatment group giving a final sample 
size of 222 Individual patient data were analysed. Only available data were used; there were 
no imputations for random missing data in this analysis.  
Radiographic data were read blind to treatment group using the modified Sharp/van der 
Heijde method (3). Essentially this method scores individual joints in the hands and feet, 
assessing joint space narrowing and erosions. The modification is the inclusion of the distal 
inter-phalangeal joints. The scores for joint space narrowing and erosions are recorded 
separately, and then added to produce a total score (range 0 ± 528). 
The following data were used to calculate the composite measures: 
 
PASDAS 
The PASDAS (Psoriatic ArthritiS Disease Activity Score) was calculated as previously 
described (4). The following variables were used: patient global VAS  (rescaled from 0 ± 
10 to 0 ± 100), physician global VAS (rescaled from 0 ± 10 to 0 ± 100),  swollen joint 
count (0-66), tender joint count (0-68) , C reactive protein (rescaled from mg/dL to mg/L), 
enthesitis (measured in GO-REVEAL as modified MASES and re-scaled to a 0 ± 6 
range, by multiplying by a factor of 6/15, for this analysis), tender dactylitis count (the 
GO-REVEAL study scored each digit from 0 ± 3 and these were re-coded to 0 ± 1, where 
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any score greater than zero equalled 1) and, finally, the physical component summary 
scale of the SF36 (PCS). The PASDAS is then given by the formula: 
3$6'$6 [¥3K\VLFLDQJOREDO9$6[¥3DWLHQWJOREDO9$6- (0.253 x 
¥6)- PCS) + (0.101 x LN (Swollen joint count + 1)) + (0.048 x LN (Tender joint count + 
1)) + (0.23 x LN (Leeds Enthesitis Count + 1)) + (0.377 LN (Dactylitis count + 1)) + (0.102 x 
LN (CRP + 1)) +2)*1.5. 
 
The GRAPPA Composite Exercise outcome measure (GRACE) 
 
The GRACE was calculated by transforming the following variables, using pre-defined 
algorithms, and expressing the total score as a mean, with a score range of 0 -1, where 
1 indicates a better state than 0 (4): swollen joint count (0-66), tender joint count (0-68), 
patient joints VAS (using data for patient pain VAS and rescaled from 0 ± 10 to 0 ± 100), 
patient global VAS (rescaled from 0 ± 10 to 0 ± 100), psoriasis area and severity 
instrument (PASI, 0 ± 72), and health assessment questionnaire (HAQ, 0 ± 3). Because  
the VAS for skin was not collected in GO-REVEAL, this component of the AMDF was 
omitted (as the index is an arithmetic mean this omission does not affect the score 
range of 0 ± 1). Because the  PsAQoL was not specifically collected, values for it were 
derived from a transformation algorithm: 
 PsAQoL =  25.355 + 2.367*HAQ ± 0.234*PCS ± 0.244*MCS 
where HAQ is the Health Assessment Questionnaire, PCS is the physical component 
summary scale of SF36, and MCS is the mental component summary scale of SF36. 
This equation was derived from the GRACE dataset(4) using linear regression in which 
the R2 value was 0.804 and the PearsoQ¶VFRUUHODWLRQEHWZHHQDFWXDODQGSUHGLFWHG
PsAQoL was 0.89.  
 
 
Disease activity in Psoriatic Arthritis (DAPSA) 
 
DAPSA was calculated as the sum of the following components: Tender joint count (0 ± 
68). Swollen joint count (0 ± 66), CRP (mg/dL), patient VAS for pain (0 ± 10) and patient 
VAS for global disease activity (0 ± 10) (5). 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Statistics 
Patients were analysed independent of allocated treatment group. All patients were 
categorised by responder status according to previously defined cut offs for response for 
each of the composite measuresUHVSRQVHFDWHJRULHVZHUHµSRRU¶µPRGHUDWH¶DQGµJRRG¶ 
(6). Statistical comparisons across outcome categories for each composite measure were 
made using analysis of variance. The proportion of people without radiographic progression 
was compared across the outcome groups for each composite measure and these data 
were compared using chi-squared statistics. 
 
Results 
201 subjects had complete data that allowed calculation of all 3 composite measures. 
Radiographic progression was greater in subjects with a poor outcome, and not seen in 
those with a good outcome. Radiographic change scores were intermediate for those with a 
moderate outcome (Table 1). Analysis of variance statistics were significant for all three 
measuresDOWKRXJKWKHµ)¶VWDWLVWLFVYDU\ (for PASDAS, GRACE and DAPSA, the magnitude 
of F was 6.11, 7.61, and 5.07 respectively.   
The proportion of subjects in whom no radiographic progression was seen (defined as 
change in vdH score of 0) are given in Table 2. The table indicates that the better the 
outcome, the greater the proportion of patients without radiographic progression, for each of 
the measures tested.   
 
Discussion 
Psoriatic arthritis is a complex condition affecting both articular and non-articular structures. 
Ideally, outcome measures used for assessing PsA in both clinical trials, as well as in the 
clinic, should capture disease involvement and activity across all domains (7). As part of the 
process of validation of composite disease activity measures external validity is a necessary 
property. In addition, it is appropriate to assess the extent to which composite measures are 
able to predict the consequences of disease activity, such as structural damage. In this study 
all three of the composite measures assessed, including those which measure across the 
disease spectrum, were able to differentiate the progression of structural damage of 
peripheral joints in relation to disease outcome.  
 
All three of the composite measures examined include a tender and swollen joint count so it 
is not surprising that radiographic progression was reflected by clinical outcome according to 
these measures, as previously noted (8). What is perhaps surprising is the inability of the 
DAPSA to distinguish those in whom no radiographic progression occurred. This is likely a 
function of the cut-offs used with this measure in this analysis. The cut-offs used herein were 
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derived from a combination of observed data (the GRACE study) and patient and physician 
opinion. They were derived in a manner similar to those for the DAS28 except that more 
weight was put on the patient opinion of response. Alternative cut-offs for the DAPSA have 
been proposed and it is likely that use of these would have produced different results (9).  
 
This study has several potential limitations. Only a proportion of the total study population 
could be used for these analyses. Also, as with all such studies, the use of the modified 
Sharp/van der Heijde method to assess structural damage in PsA is open to question. 
Psoriatic arthritis is a disease that affects small joints of the hands and feet differently to RA, 
the disease in which the original SVDH method was developed (10). It could also be argued 
that the time frame for the development of structural damage in the GO-REVEAL was too 
short. The relatively large percentage of patients who did not experience any  radiographic 
progression, and the relatively small mean scores for changes in radiographic scores would 
support this assertion. Nevertheless, significant differences in structural damage were 
demonstrated according to outcome status and this may reflect the fact that enrolment of 
patients into this clinical trial was predicated upon active peripheral arthritis.  
 
In summary, all composite measures tested in this analysis demonstrated a relationship 
between radiographic progression and clinical outcome, further vindicating their validity in 
this condition.  
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Table 1. Total radiographic change score for each response category for each outcome 
measure. Figures are mean (standard error of mean). F = statistic from analysis of variance. 
 
 
  
 Good response Moderate response Poor response F p 
PASDAS 
 
- 0.27 ± 0.15 
N = 86 
+ 0.18 ± 0.10 
N = 76 
+ 0.49 ± 0.19 
N = 39 
6.11 0.003 
GRACE 
 
- 0.33 ± 0.17 
N = 72 
+ 0.05 ± 0.10 
N = 75 
+ 0.51 ± 0.16 
N = 54 
7.61 0.001 
DAPSA - 0.22 ± 0.23 
N=46 
- 0.06 ± 0.10 
N=104 
+ 0.50 ± 0.16 
N=51 
5.07 0.007 
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Table 2. Number (percentage within category) of people with no radiographic progression by 
response category for each composite measure. The chi-squared statistic is derived from the 
3x2 table generated for each outcome measure. 
 
 
 
 
 
 
 
Good response Moderate response Poor response ȋ2 p 
PASDAS 
 
71 (83) 51 (67) 24 (62) 7.9 0.02 
GRACE 
 
56 (80) 55 (75) 33 (61) 5.8 0.05 
DAPSA 
 
35 (76) 79 (76) 32 (63) 3.4 0.19 
